Moderna shares up 2% as skin cancer vaccine shows sustained benefit in five-year follow-up

Moderna and Merck said on Tuesday their ⁠experimental personalized vaccine continued to cut the risk of death or recurrence of the most deadly skin cancer five years after the treatment started.